We’re delighted to announce that Kiana Hassankhani has joined our CNS research team as a Research Scientist! 🎉 Kiana brings valuable expertise and fresh perspectives in neuroscience and pharmacology, which will strengthen our capabilities in CNS drug discovery and preclinical research. Her scientific insight, dedication, and collaborative mindset make her a fantastic addition to the Pharmidex family. We're excited to see the impact of her work as we continue advancing innovative solutions for our partners and patients.  Welcome Kiana, we’re thrilled to have you on board! 👏

With our cutting-edge in silico drug discovery capabilities 👉 https://www.pharmidex.com/In-silico Pharmidex is committed to accelerating the development of novel therapies targeting GLP-1 receptors, a promising path in the fight against obesity and type 2 diabetes. By combining our in silico expertise, including molecular docking, virtual screening and structure-based design, with our well-established in vivo obesity models, we offer a powerful, integrated platform to uncover and validate new therapeutic candidates more efficiently. Whether you're a pharma company, CRO, biotech, or academic institution, Pharmidex is ready to collaborate and support your discovery efforts from computational predictions to real-world preclinical validation. 🤝 Let’s combine strengths and accelerate innovation in metabolic disease research to improve human health globally.